BCB Bancorp (BCBP) Q3 2026 earnings summary

Executive summary

• Q3 net loss attributable to common stockholders was $132.5M, versus $14.8M net loss in Q2 and $3.8M net income in Q3 2025; diluted EPS was $(6.92).

• Strategic actions included a $98.0M public offering, $204.3M of problem-loan sales, and transfers of $100.9M in loans to held-for-sale status.

• Management said the balance sheet was substantially de-risked, while emphasizing continued work on risk management, operating performance, and sustainable profitability.

Financial highlights

• Q3 net interest income was $22.6M, down 4.7% year over year; nine-month net interest income was $68.8M, essentially unchanged year over year.

• Q3 provision for credit losses was $115.0M versus $4.1M a year earlier; net charge-offs were $89.7M versus $16.9M.

• Non-interest income was $5.2M, including a $3.3M gain on OREO sale; non-interest expense rose 31.6% to $21.8M, including severance and higher professional fees.

• Nine-month net loss attributable to common stockholders was $142.8M versus $1.9M in 9M 2025; diluted EPS was $(7.98) versus $(0.11).

Outlook and guidance

• The remaining $67.6M of loans held for sale is intended for disposition; final prices may differ from estimated fair values, and completion on acceptable terms is uncertain.

• Plans include exiting cannabis banking and resolving problem loans; management expected the remaining cannabis portfolio sale and several loan resolutions in Q4.

• Q4 will retain some elevated legal and professional costs related to the cannabis transaction and balance-sheet cleanup; more expense guidance was expected with Q4 results.

• The $59.9M deferred-tax valuation allowance may be reconsidered if the quantity and quality of earnings support reversal; management cited end-2027 as a possible timing.

• Residential mortgage, home-equity, and consumer originations were discontinued; new commercial lending was temporarily suspended pending portfolio review.